{
    "root": "f4843a89-4cfb-40de-8399-a7449b4865e2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Methadone Hydrochloride",
    "value": "20250401",
    "ingredients": [
        {
            "name": "METHADONE HYDROCHLORIDE",
            "code": "229809935B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50140"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30769"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113455"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "methadone hydrochloride oral concentrate ( intensol\u2122 ) contains methadone , opioid agonist indicated : \u2022management pain severe enough require daily , around-the-clock , long-term opioid treatment alternative treatment options inadequate . limitations obecause risks addiction , abuse , misuse opioids , even recommended doses , greater risks overdose death long-acting opioids [ ( 5.5 ) ] , reserve methadone hydrochloride intensol\u2122 patients alternative analgesic treatment options ( e.g . , non-opioid analgesics immediate-release opioid analgesics ) ineffective , tolerated , would otherwise inadequate provide sufficient management pain . omethadone hydrochloride intensol\u2122 indicated as-needed ( prn ) analgesic . \u2022detoxification treatment opioid addiction ( heroin morphine-like drugs ) . \u2022maintenance treatment opioid addiction ( heroin morphine-like drugs ) , conjunction appropriate social medical services . limitations methadone products used treatment opioid addiction detoxification maintenance programs subject conditions distribution required 21 cfr , title 42 , sec . 8 [ ( 2.1 ) ] .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 strongly consider prescribing naloxone time methadone initiated renewed patients treated methadone may risk opioid overdose initiation titration , case relapse illicit . ( 2.3 ) \u2022 initiation detoxification maintenance treatment : single dose 20 30 mg may sufficient suppress withdrawal syndrome . ( 2.4 ) \u2022 maintenance treatment : stability commonly achieved doses 80 120 mg/day . ( 2.5 ) \u2022 abruptly discontinue methadone physically dependent patient . ( 2.6 , 5.15 ) management pain \u2022 prescribed healthcare providers knowledgeable potent opioids management chronic pain . ( 2.10 ) \u2022 lowest effective shortest duration consistent individual patient treatment goals . ( 2.10 ) \u2022 individualize dosing based severity pain , patient response , prior analgesic experience , risk factors addiction , abuse , misuse . ( 2.10 ) \u2022 opioid na\u00efve patients , initiate methadone treatment 2.5 mg every 8 12 hours . ( 2.10 ) \u2022 convert methadone another opioid , available conversion factors obtain estimated dose . ( 2.10 ) \u2022 titrate slowly dose increases frequent every 3 5 days . ( 2.10 ) \u2022 abruptly discontinue methadone hydrochloride intensol \u2122 physically dependent patient rapid discontinuation opioid analgesics resulted serious withdrawal symptoms , uncontrolled pain , suicide . ( 2.12 , 5.15 )",
        "doid_entities": [
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "methadone hydrochloride oral concentrate , usp ( intensol tm ) , 10 mg per ml 10 mg per ml oral concentrate supplied clear , colorless solution . ndc 0054-3553-44 : bottle 30 ml calibrated syringe [ graduations 0.25 ml ( 2.5 mg ) , 0.5 ml ( 5 mg ) , 0.75 ml ( 7.5 mg ) , 1 ml ( 10 mg ) syringe ] . store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) , excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) . [ usp controlled room temperature . ] store methadone hydrochloride intensol\u2122 securely dispose properly [ patient counseling information ( 17 ) ] .",
    "adverseReactions": "methadone hydrochloride intensol\u2122 contraindicated patients : \u2022significant respiratory depression [ ( 5.1 ) ] . \u2022acute severe bronchial asthma unmonitored setting absence resuscitative equipment [ ( 5.8 ) ] . \u2022known suspected gastrointestinal obstruction , including paralytic ileus [ ( 5.13 ) ] . \u2022hypersensitivity ( e.g . , anaphylaxis ) methadone ingredient methadone hydrochloride intensol\u2122 [ ( 6 ) ] .",
    "indications_original": "Methadone Hydrochloride Oral Concentrate (Intensol\u2122) contains methadone, an opioid agonist indicated for the:\n                  \n                     \n                        \u2022Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.\n                  \n                  \n                     Limitations of Use\n                  \n                  \n                     \n                        \u00a0\n                        \n                           \n                              oBecause of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with long-acting opioids [see Warnings and Precautions (5.5)], reserve Methadone Hydrochloride Intensol\u2122 for use in patients for whom alternative analgesic treatment options (e.g., non-opioid analgesics or immediate-release opioid analgesics) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.\n                           \n                              oMethadone Hydrochloride Intensol\u2122 are not indicated as an as-needed (prn) analgesic.\n                        \n                     \n                     \n                        \u2022Detoxification treatment of opioid addiction (heroin or other morphine-like drugs).\n                     \n                        \u2022Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services.\n                  \n                  \n                     Limitations of Use\n                  \n                  Methadone products used for the treatment of opioid addiction in detoxification or maintenance programs are subject to the conditions for distribution and use required under 21 CFR, Title 42, Sec. 8 [see Dosage and Administration (2.1)].",
    "contraindications_original": "\u2022 Strongly consider prescribing naloxone at the time methadone is initiated or renewed because patients being treated with methadone may be at risk for opioid overdose during initiation or titration, or in the case of relapse to illicit use. ( 2.3 ) \u2022 Initiation of Detoxification and Maintenance Treatment: A single dose of 20 to 30 mg may be sufficient to suppress withdrawal syndrome. ( 2.4 ) \u2022 Maintenance Treatment: Clinical stability is most commonly achieved at doses between 80 to 120 mg/day. ( 2.5 ) \u2022 Do not abruptly discontinue methadone in a physically dependent patient. ( 2.6 , 5.15 ) Management of Pain \u2022 To be prescribed only by healthcare providers knowledgeable in use of potent opioids for management of chronic pain. ( 2.10 ) \u2022 Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. ( 2.10 ) \u2022 Individualize dosing based on the severity of pain, patient response, prior analgesic experience, and risk factors for addiction, abuse, and misuse. ( 2.10 ) \u2022 For opioid na\u00efve patients, initiate methadone treatment with 2.5 mg every 8 to 12 hours. ( 2.10 ) \u2022 To convert to methadone from another opioid, use available conversion factors to obtain estimated dose. ( 2.10 ) \u2022 Titrate slowly with dose increases no more frequent than every 3 to 5 days. ( 2.10 ) \u2022 Do not abruptly discontinue Methadone Hydrochloride Intensol \u2122 in a physically dependent patient because rapid discontinuation of opioid analgesics has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. ( 2.12 , 5.15 )",
    "warningsAndPrecautions_original": "Methadone Hydrochloride Oral Concentrate, USP (Intensol\n                        TM), 10 mg per mL\n                  \n                  \n                     10 mg per mL oral concentrate is supplied as a clear, colorless solution. \n                  \n                  NDC 0054-3553-44: Bottle of 30 mL with calibrated syringe [graduations of 0.25 mL (2.5 mg), 0.5 mL (5 mg), 0.75 mL (7.5 mg), and 1 mL (10 mg) on the syringe].\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F), with excursions permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F). [See USP Controlled Room Temperature.]\n                  Store Methadone Hydrochloride Intensol\u2122 securely and dispose of properly [see Patient Counseling Information (17)].",
    "adverseReactions_original": "Methadone Hydrochloride Intensol\u2122 is contraindicated in patients with: \n                  \n                     \n                        \u2022Significant respiratory depression [see Warnings and Precautions (5.1)]. \n                     \n                     \n                        \u2022Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see Warnings and Precautions (5.8)]. \n                     \n                     \n                        \u2022Known or suspected gastrointestinal obstruction, including paralytic ileus [see Warnings and Precautions (5.13)].\n                     \n                     \n                        \u2022Hypersensitivity (e.g., anaphylaxis) to methadone or any other ingredient in Methadone Hydrochloride Intensol\u2122 [see Adverse Reactions (6)].",
    "drug": [
        {
            "name": "Methadone Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50140"
        }
    ]
}